Toxicogenomics Investigation Under the eTOX Project

Olivier Taboureau, Anne Hersey, Karine Marie Laure Audouze, Laurent Gautier, Ulrik Plesner Jacobsen, Ruth Akhtar, Francis Atkinson, John P. Overington, Søren Brunak

Research output: Contribution to journalJournal articleResearchpeer-review

288 Downloads (Pure)


Attrition of drug candidates during pre-clinical development due to toxicity, especially hepatotoxicity and nephrotoxicity, is an important and continuing problem in the pharmaceutical industry. The reasons for this trend may be multifactorial and there is a need to improve toxicity testing paradigms within the industry. Microarray technologies have the ability to generate massive amounts of gene expression information as an initial step to decipher the molecular mechanisms of toxicologic changes, i.e. toxicogenomics. In the context of the eTOX consortium, one of public private partnership within the framework of the European Innovative Medicines Inititative (IMI), we will discuss here how the integration and analysis of toxicogenomics data can help to understanding the mechanism of toxicity
of a compound and so reduce the risk of late-stage failure in pharmaceutical development.
Original languageEnglish
JournalJournal of Pharmacogenomics & Pharmacoproteomics
Number of pages5
Publication statusPublished - 2012


  • Toxicogenomics
  • Gene expression;
  • Drugs
  • Rats

Fingerprint Dive into the research topics of 'Toxicogenomics Investigation Under the eTOX Project'. Together they form a unique fingerprint.

Cite this